{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:01:52Z","timestamp":1768402912718,"version":"3.49.0"},"reference-count":29,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>We report the case of a patient who developed antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) after receiving the coronavirus disease 2019 (COVID-19) vaccine BNT162b (Pfizer\u2013BioNTech). A 37-year-old Japanese woman had been taking propylthiouracil for Graves\u2019 disease. She had erythema on her forearm on the 12th day after receiving the first dose of the vaccine, fever on the 13th day, and redness and swelling of her left auricle on the 25th day. Her serum myeloperoxidase-ANCA and proteinase 3-ANCA levels, which were negative before the Graves\u2019 disease treatment, were elevated. She had unilateral auricular symptoms but no other typical relapsing polychondritis findings. She was diagnosed with propylthiouracil-induced AAV. She was treated with oral glucocorticoids, and her symptoms improved. Propylthiouracil is considered to be the main cause of the onset of AAV in this case, but it cannot be ruled out that BNT162b may have had some effect on the onset of the disease. Although the development of propylthiouracil-induced AAV in this case may have been incidental and unrelated to the vaccination, this report provides important data for evaluating the safety of the vaccine.<\/jats:p>","DOI":"10.3390\/vaccines9080842","type":"journal-article","created":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T21:46:44Z","timestamp":1627854404000},"page":"842","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis after COVID-19 Vaccination"],"prefix":"10.3390","volume":"9","author":[{"given":"Saki","family":"Okuda","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Kindai University Nara Hospital, 1248-1, Otodacho, Ikoma 630-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9472-4103","authenticated-orcid":false,"given":"Yasuaki","family":"Hirooka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kindai University Nara Hospital, 1248-1, Otodacho, Ikoma 630-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kindai University Nara Hospital, 1248-1, Otodacho, Ikoma 630-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,31]]},"reference":[{"key":"ref_1","unstructured":"Coronavirus Resource Center (2021, June 22). Johns Hopkins University and Medicine. Available online: https:\/\/coronavirus.jhu.edu\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","article-title":"BNT162b2 mRNA COVID-19 Vaccine: First Approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"E133","DOI":"10.1002\/ajh.26106","article-title":"Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine","volume":"96","author":"Tarawneh","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ajh.26132","article-title":"Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination","volume":"96","author":"Lee","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e242220","DOI":"10.1136\/bcr-2021-242220","article-title":"Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination","volume":"14","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_8","first-page":"e14853","article-title":"Newly diagnosed idiopathic thrombocytopenia post COVID-19 vaccine Administration","volume":"13","author":"Idogun","year":"2021","journal-title":"Cureus"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.ajkd.2019.04.031","article-title":"ANCA-associated vasculitis: Core curriculum 2020","volume":"75","author":"Geetha","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1440-1797.2009.01100.x","article-title":"Review article: Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"14","author":"Gao","year":"2009","journal-title":"Nephrology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nrneph.2012.108","article-title":"Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis","volume":"8","author":"Chen","year":"2012","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00005792-197605000-00001","article-title":"Relapsing polychondritis: Prospective study of 23 patients and a review of the literature","volume":"55","author":"McAdam","year":"1976","journal-title":"Medicine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/ard.52.5.384-b","article-title":"Antineutrophil cytoplasmic antibodies in polychondritis","volume":"52","author":"Papo","year":"1993","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e9378","DOI":"10.1097\/MD.0000000000009378","article-title":"ANCA positive relapsing polychondritis, Graves disease, and suspected moyamoya disease: A case report","volume":"96","author":"Xuan","year":"2017","journal-title":"Medicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7326\/0003-4819-104-1-74","article-title":"Relapsing polychondritis. Survival and predictive role of early disease manifestations","volume":"104","author":"Michet","year":"1986","journal-title":"Ann. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.7326\/0003-4819-129-2-199807150-00011","article-title":"Relapsing polychondritis","volume":"129","author":"Trentham","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_18","first-page":"e15259","article-title":"A rare case of SARS-CoV-2-induced microscopic polyangiitis","volume":"13","author":"Allena","year":"2021","journal-title":"Cureus"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00296-021-04914-3","article-title":"ANCA-associated vasculitis after COVID-19","volume":"41","author":"Turkmen","year":"2021","journal-title":"Rheumatol. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/art.41671","article-title":"COVID-19 Reinfection in a patient receiving immunosuppressive treatment for antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Gulati","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_21","first-page":"1","article-title":"Mechanisms of thrombosis in ANCA-associated vasculitis","volume":"9","author":"Misra","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.5152\/eurjrheum.2020.2067","article-title":"Immunotherapy for ANCA-associated vasculitis during the COVID-19 pandemic","volume":"7","author":"Gapud","year":"2020","journal-title":"Eur. J. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.toxrep.2021.04.003","article-title":"Safety of COVID-19 vaccines administered in the EU: Should we be concerned?","volume":"8","author":"Calina","year":"2021","journal-title":"Toxicol. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/cmi.2017.151","article-title":"Vaccine-induced autoimmunity: The role of molecular mimicry and immune crossreaction","volume":"15","author":"Segal","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"617089","DOI":"10.3389\/fimmu.2020.617089","article-title":"Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: Implications for autoimmune diseases","volume":"11","author":"Vojdani","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"108480","DOI":"10.1016\/j.clim.2020.108480","article-title":"Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases","volume":"217","author":"Vojdani","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"108665","DOI":"10.1016\/j.clim.2021.108665","article-title":"Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to \u201cpotential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases\u201d","volume":"224","author":"Talotta","year":"2021","journal-title":"Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1089\/thy.2000.10.595","article-title":"Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves\u2019 disease","volume":"10","author":"Sera","year":"2000","journal-title":"Thyroid"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1210\/jc.2008-2700","article-title":"Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs","volume":"94","author":"Noh","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/8\/842\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:38:36Z","timestamp":1760164716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/8\/842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,31]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["vaccines9080842"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9080842","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,31]]}}}